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Editorial on the Research Topic
In vivo Imaging in Pharmacological Research
The discovery and development of a biologically active molecule with therapeutic properties is an
increasingly complex task, highly unpredictable at the early stages and frequently marked, in the
end, by high rates of failure. As a consequence, the overall process leading to the production of a
successful drug is very long and costly. The improvement of the net outcome in drug discovery
and development would require, amongst other important factors, a good understanding of the
molecular events that characterize the disease or pathology in order to better identify likely targets
of interest, to optimize the interaction of an active agent (a small molecule or a macromolecule of
natural or synthetic origin) with those targets, and to facilitate the study of the pharmacokinetics,
pharmacodynamics and toxicity of an active agent in both suitable models and human subjects.
This series of articles has been brought together to highlight new developments and applications
of imaging techniques with the objective of performing pharmacological studies in vivo, in animal
models as well as in humans. Imaging has the ability to study various biological and chemical
processes non-invasively in living subjects in a longitudinal manner. For this reason, imaging
technologies have become an integral part of the drug-discovery and development program and
are commonly used in both preclinical and clinical stages. The anatomical, functional, metabolic,
and molecular information that becomes accessible through imaging provides invaluable insights
into disease mechanisms and mechanisms of drug action.
Computerized tomography (CT) andmagnetic resonance imaging (MRI) belong to the so called
anatomy-based imaging techniques. They exploit intrinsic tissue characteristics as the source of
image contrast. However, both modalities may also rely on the use of agents to highlight some
particular contrast. The development of MRI contrast agents has been briefly discussed by Terreno
and Aime. The great advantage of CT and MRI in the context of drug research is their translational
nature. Thus, they may be used for compound testing in animal models of diseases and further
also in clinical studies. Here, Ashton et al. reviewed non-contrast-enhanced and contrast-enhanced
micro-CT applications for the study of anatomy and function in small rodents. Recent advances
of cardiovascular, neurovascular and renal MRI in small rodents were addressed by Niendorf
et al.; Jonckers et al. described the way functional MRI (fMRI) can be used to study the effects
of pharmacological modulations on brain function in a non-invasive and longitudinal manner.
Finally, Marzola et al. highlighted the use of imaging, especially micro-CT and MRI, for the in vivo
identification, quantification, and functional characterization of adipose tissues in animal models
of obesity, mainly from the point of view of biophysics and physiology.
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As the domain of imaging sciences transitions from
anatomical/functional to molecular applications, the
development of molecular probes becomes crucial for the
advancement of the field. Positron emission tomography (PET)
and single photon emission computed tomography (SPECT)
are molecular imaging techniques of great interest within
pharmacological research. They have the ability to provide
biomarkers that permit spatial assessment of pathophysiological
molecular changes and therefore objectively evaluate and follow
up therapeutic responses. They are known primarily for their
clinical applications, however, animal studies are also feasible,
emphasizing the translational character of these techniques.
Here, Declercq et al. illustrated the use of SPECT and PET
in the context of drug development for Alzheimer’s disease
(AD), specifically discussing a number of biomarkers that are
supporting emerging clinical therapies for this disease.
Targeted therapy with monoclonal antibodies (mAbs) is
an avenue pursued in the context of personalized medicine,
particularly for cancer patients. The assessment of in vivo
biodistribution and tumor targeting of mAbs to predict toxicity
and efficacy is an important step toward drug development
for individualized treatments. Jauw et al. discussed how PET
employing zirconium-89 (89Zr)-labeled mAbs, an approach also
termed 89Zr-immuno-PET, can be used to visualize and quantify
the uptake of radiolabeled mAbs in tumors. Overall, 89Zr-
immuno-PET provides imaging biomarkers to assess target
expression as well as tumor targeting of mAbs.
Ultrasound is a classical diagnostic imaging technique often
used to locate a source of a disease or to exclude any pathology.
It is largely used to visualize internal body structures, such
as tendons, muscles, joints or vessels, and internal organs.
Besides its ability to provide anatomical information, ultrasound
can also display information on blood flow, motion of tissue
over time, and tissue stiffness. Compared to other prominent
methods of medical imaging, ultrasound has several advantages,
including the acquisition of images in real-time, it is portable
and can be brought to the bedside, it is substantially lower in
cost and does not use harmful ionizing radiation. Drawbacks
of ultrasonography include limited field of view, difficulty in
imaging structures behind bone and air, and its dependence
on skilled operators. Seitz et al. showed that ultrasound is
sufficiently reliable to measure acute and chronic changes in the
diameter of splanchnic veins in intact rats. Although ultrasound
imaging of the abdominal vessels is not novel in experimental
research or in the clinics, assessment of diameter changes in
multiple splanchnic vessels is new as they relate to venous
capacitance.
Recently, ultrasound has also entered the arena of molecular
imaging. Paefgen et al. reviewed here the development of
bubble-based contrast agents for ultrasound imaging and
for imaging drug delivery. The basis for molecular imaging
applications is the coupling to the shell of bubbles of specific
ligands that bind to marker molecules in the area of interest.
Also, bubbles may be loaded with or attached to drugs,
peptides or genes. By applying ultrasound pulses, the bubbles
are destroyed, leading to a local release of the entrapped
agent. The use of microbubble-assisted ultrasound to deliver
chemotherapeutic agents has been extensively discussed by
Lammertink et al. One specific class of agents that might
be of interest for such delivery are S-tanathin functionalized
liposomes, as presented here by Fan et al. S-thanatin is a short
antimicrobial peptide with selective antibacterial activity (Wu
et al., 2010).
Optical imaging adds to the realm of molecular imaging
approaches. Main advantages of optical imaging are safety
and cost-effectiveness. Major drawbacks, however, are the
high scattering and high absorption of light in living tissues.
Arranz and Ripoll described the latest advances in optical
in vivo imaging with pharmacological applications, with special
focus on the development of new optical imaging probes
in order to overcome the strong absorption introduced by
different tissue components, especially hemoglobin, and the
development of multimodal imaging systems in order to
overcome the resolution limitations imposed by scattering.
Despite being mostly limited to small rodents, there is a large
interest for optical imaging in the context of pharmacological
research, as optical imaging is useful for selecting and
validating potential novel probes in an economic and safe
(radiation free). The in vivo performance of optical probes
may predict the outcome of the ensuing and much more
involved SPECT/PET tracer development (Sandanaraj et al.,
2010).
Animal models have in general been considered of importance
in the drug discovery process. On the other hand, the widespread
use and evolution of imaging would not have been possible
without animal studies. Animal models have allowed, for
instance, the technical development of different imaging tools
and probes. Santos et al. have critically discussed the value of
animal models in the context of cardiovascular imaging.
The focus in this series has been dedicated to in vivo
macroscopic imaging applications within pharmacological
research. Nonetheless, microscopic imaging has also an
important role to play in this domain. As an example, Xu
highlighted the latest advances in hepatotoxicity, cardiotoxicity,
and genetic toxicity tests utilizing cellular imaging as a screening
strategy.
In the domain of drug discovery, the pharmacological and
biomedical questions constitute the center of attention. In this
sense, it is fundamental to keep in mind the strengths and
limitations of each analytical or imaging technique. In this series,
our aim was to illustrate the fact that the judicious application
of a given technique to search for answers to manifold questions
arising during a long and painstaking path will continue to
rely on imaging as a must-have tool in drug discovery and
development.
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